References

  1. Repatha® (evolocumab injection) Product Monograph, Amgen Canada Inc., September 27, 2023.
  2. IQVIA. National TRx volume claims database. 2021.
  3. Pearson GJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol 2021;37(8):1129-50.
  4. Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22.
  5. Robinson JG, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311(18):1870-82.
  6. Raal FJ, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385(9965):331-40.
  7. Sabatine MS, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J 2016;173:94-101.
  8. Genest J, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 2014;30(12):1471-81.
  9. Brunham LR, et al. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Can J Cardiol 2018;34(12):1553-63.
  10. Health Canada. Notice of Compliance Search. 2023. Available at: https://health-products.canada.ca/noc-ac/index-eng.jsp. Retrieved May 9, 2022.
  11. Amgen Canada Inc. Data on file (private insurance coverage). 2023.
  12. BC PharmaCare. Limited Coverage Drugs – evolocumab. 2023. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drugs-evolocumab. Retrieved May 9, 2023.
  13. Alberta Blue Cross. Interactive Drug Benefit List. 2023. Available at: https://idbl.ab.bluecross.ca/idbl/. Retrieved May 9, 2023.
  14. Saskatchewan Go. Saskatchewan drug plan. 2023. Available at: http://formulary.drugplan.ehealthsask.ca/SearchFormulary. Retrieved May 9, 2023.
  15. Manitoba Pharmacare. Manitoba Drug Benefits and Interchangeability Formulary. 2023. Available at: https://www.gov.mb.ca/health/mdbif/. Retrieved May 9, 2023.
  16. Government of Ontario. Ontario Drug Benefit Formulary/Comparative Drug Index. 2023. Available at: https://www.formulary.health.gov.on.ca/formulary/. Retrieved May 9, 2023.
  17. RAMQ (official mark of the Régie de l'assurance maladie du Québec). List of Medications. 2023. Available at: https://www.ramq.gouv.qc.ca/en/about-us/list-medications. Retrieved May 9, 2023.
  18. Government of New Brunswick. NB Drug Plans Formulary Update. 2023. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf. Retrieved May 9, 2023.
  19. Nova Scotia Pharmacare. Exception Status Drugs. 2023. Available at: https://novascotia.ca/dhw/pharmacare/exception-status-drugs.asp. Retrieved May 9, 2023.
  20. PEI Pharmacare Formulary. Available at: https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf. Retrieved May 9, 2023.
  21. Newfoundland and Labrador Prescription Drug Program. Available at: https://www.health.gov.nl.ca/health/prescription/criteria/Evolocumab_Repatha.pdf. Retrieved May 9, 2023.

You are now leaving the Repatha.ca website

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to another Amgen Canada site?

Yes, leave Repatha.ca

You are now leaving the Repatha.ca website. Please note that these links are being provided as a convenience and for informational purposes only.

PROCEED